Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Conditions
Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Pacific Cancer Medical Center Inc, Anaheim, California, United States
Loma Linda University Cancer Center, Loma Linda, California, United States
Ucla Department Of Medicine, Los Angeles, California, United States
Stanford University School Of Medicine, Stanford, California, United States
Kaiser Permanente Medical Center, Vallejo, California, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
University Of Chicago, Chicago, Illinois, United States
Central Indiana Cancer Centers, Indianapolis, Indiana, United States
University Of Kansas Medical Center, Westwood, Kansas, United States
Dana Faber Cancer Institute, Boston, Massachusetts, United States
University Of Michigan Medical Center, Ann Arbor, Michigan, United States
Wayne State University, Detroit, Michigan, United States
John Theurer Cancer Center, Hackensack, New Jersey, United States
Oregon Health & Sci Univ, Portland, Oregon, United States
Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
Ut Southwestern Medical Center At Dallas, Dallas, Texas, United States
The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States
Local Institution, Buenos Aires, Buenos Aires, Argentina
Local Institution, Buenos Aires, Buenos Aires, Argentina
Local Institution, Capital Federal, Buenos Aires, Argentina
Local Institution, Adelaide, South Australia, Australia
Local Institution, Mont-godinne, Belgium
Local Institution, Curitiba, Paraná, Brazil
Local Institution, Rio de Janeiro, Rio de Janeiro, Brazil
Local Institution, Campinas, São Paulo, Brazil
Local Institution, São Paulo, São Paulo, Brazil
Local Institution, São Paulo, São Paulo, Brazil
Local Institution, Toronto, Ontario, Canada
Local Institution, Montreal, Quebec, Canada
Local Institution, Helsinki, Finland
Local Institution, Lille, France
Local Institution, Lyon, France
Local Institution, Nantes, France
Local Institution, Paris, France
Local Institution, Pessac, France
Local Institution, Poitiers, France
Local Institution, Strasbourg, France
Local Institution, Hamburg, Germany
Local Institution, Leipzig, Germany
Local Institution, Mannheim, Germany
Local Institution, Budapest, Hungary
Local Institution, Dublin, Dublin, Ireland
Local Institution, Ramat Gan, Israel
Local Institution, Bologna, Italy
Local Institution, Naples, Italy
Local Institution, Orbassano (to), Italy
Local Institution, Roma, Italy
Local Institution, Trondheim, Norway
Local Institution, Lima, Lima Province, Peru
Local Institution, Lima, Lima Province, Peru
Local Institution, Katowice, Poland
Local Institution, Krakow, Poland
Local Institution, Lodz, Poland
Local Institution, Lublin, Poland
Local Institution, Warsaw, Poland
Local Institution, Moscow, Russia
Local Institution, Saint Petersburg, Russia
Local Institution, Groenkloof, Gauteng, South Africa
Local Institution, Parktown, Gauteng, South Africa
Local Institution, Jeollanam-do, South Korea
Local Institution, Seoul, South Korea
Local Institution, Barcelona, Spain
Local Institution, Gothenburg, Sweden
Local Institution, Lund, Sweden
Local Institution, Stockholm, Sweden
Local Institution, Umeå, Sweden
Local Institution, Uppsala, Sweden
Local Institution, Basel, Switzerland
Local Institution, Bangkok, Thailand
Local Institution, London, Greater London, United Kingdom
Local Institution, Glasgow, Scotland, United Kingdom
Local Institution, Newcastle, Tyne and Wear, United Kingdom
Study leads
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb